MARKET

CTNM

CTNM

Contineum Therapeutics
NASDAQ
16.70
-0.87
-4.95%
After Hours: 16.70 0 0.00% 16:10 09/04 EDT
OPEN
17.38
PREV CLOSE
17.57
HIGH
17.71
LOW
16.50
VOLUME
346.23K
TURNOVER
--
52 WEEK HIGH
17.79
52 WEEK LOW
8.60
MARKET CAP
628.27M
P/E (TTM)
-9.6132
1D
5D
1M
3M
1Y
5Y
1D
Show Me The Money: Contineum Therapeutics' Turnaround From Lows To New Highs
NASDAQ · 2d ago
Contineum Therapeutics, Inc. Class A (CTNM) Receives a Buy from RBC Capital
TipRanks · 3d ago
Contineum Therapeutics: Buy Rating Reiterated with PIPE-791 Upside Potential and Unchanged $26 Price Target
TipRanks · 4d ago
Weekly Report: what happened at CTNM last week (0824-0828)?
Weekly Report · 6d ago
Contineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare Conference
Barchart · 08/25 15:05
Weekly Report: what happened at CTNM last week (0817-0821)?
Weekly Report · 08/24 10:30
Contineum Therapeutics, Inc. Class A (CTNM) Gets a Hold from Morgan Stanley
TipRanks · 08/17 12:58
Weekly Report: what happened at CTNM last week (0810-0814)?
Weekly Report · 08/17 10:31
More
About CTNM
Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing novel, oral small molecule therapies for neuroscience, inflammation and immunology (NI&I) indications with significant unmet need. It is advancing a pipeline of internally developed programs with multiple drug candidates in clinical trials. Its lead asset, PIPE-791, is a novel, brain-penetrant, small-molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) in development for idiopathic pulmonary fibrosis (IPF), progressive multiple sclerosis (PrMS), and chronic pain. Its second drug candidate, PIPE-307, is a novel, small-molecule selective inhibitor of the muscarinic type 1 receptor (M1R), in development for depression and relapse-remitting multiple sclerosis (RRMS). The Company is also conducting preclinical and discovery-phase experiments targeting other NI&I indications where its internally discovered molecules may have therapeutic potential.

Webull offers Contineum Therapeutics Inc stock information, including NASDAQ: CTNM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CTNM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CTNM stock methods without spending real money on the virtual paper trading platform.